AZD8701 is an experimental immunotherapy drug which works by targetting a molecule called FOXP3. This type of treatment works by “taking the brakes off” of immune cells in the body, allowing them to more aggressively attack and destroy cancer cells.
Since this drug is still in the clinical trial phase, it has the placeholder name AZD8701 rather than a commercial trade name.
Durvalamab (Imfinzi®) is a Health Canada approved immunotherapy that is currently used in the treatment of lung cancer, but is similar to another drug called Atezolizumab (Tecentriq®) which is already approved for the treatment of Kidney Cancer in Canada. These drugs work by targeting a molecule called PD-L1 which enables the immune system to better recognize and destroy cancer cells.
This study will have two treatment groups that will be assigned by the physician handling your care:
Group 1: AZD8701 alone
Group 2: AZD8701 with Durvalamab
In order to maximize effectiveness and minimize side effects, different doses of each drug will be used to determine the optimal dosage of these medications.
There is no control group in the study, so there will be no “placebo”, and all patients will receive treatment.
- Clear cell kidney cancer
- Advanced kidney cancer that cannot be removed by surgery
- No further drug treatments are available or recommended
- No prior treatment with a PD-L1-targeted therapy
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorNot given||LocationToronto, ON||Trial StatusNot Yet Recruiting|